You are here

Article Text

Article menu
Education
Review
Chronic abdominal pain in inflammatory bowel disease: a practical guide
Free
  1. Samantha Baillie1,
  2. Christine Norton2,
  3. Sonia Saxena3,
  4. Richard Pollok1
  1. 1 Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK
  2. 2 Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK
  3. 3 Primary Care and Public Health, Imperial College London, London, UK
  1. Correspondence to Dr Samantha Baillie, Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, UK; s.baillie1{at}nhs.net

Abstract

Pain is common in inflammatory bowel disease (IBD), yet many patients feel their pain is not addressed by healthcare professionals. Listening to a patient’s concerns about pain, assessing symptoms and acknowledging the impact these have on daily life remain crucial steps in addressing pain in IBD. While acute pain may be effectively controlled by pain medication, chronic pain is more complex and often pharmacological therapies, particularly opioids, are ineffective. Low-dose tricyclic antidepressants and psychological approaches, including cognitive–behavioural therapy, have shown some promise in offering effective pain management while lifestyle changes such as a trial of low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet in those with overlapping irritable bowel syndrome may also reduce pain. Patients benefit from a long-term, trusting relationship with their healthcare professional to allow a holistic approach combining pharmacological, psychological, lifestyle and dietary approaches to chronic pain. We present a practical review to facilitate management of chronic abdominal pain in IBD.

  • INFLAMMATORY BOWEL DISEASE
  • ULCERATIVE COLITIS
  • CROHN'S DISEASE
  • ABDOMINAL PAIN
  • CLINICAL DECISION MAKING

https://doi.org/10.1136/flgastro-2023-102471

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key points

    • Aim to create a long-term, trusting relationship with patients to allow an individualised, patient-specific, holistic approach to chronic pain management.

    • Ensure that modifiable causes for pain have been assessed, investigated and treated.

    • Treating coexisting irritable bowel syndrome may help to manage chronic inflammatory bowel disease pain. This includes antispasmodics, fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet and tricyclic antidepressant medication.

    • Avoid opioid medication as this has no proven benefit and is associated with poorer outcomes.

    • Psychological therapies including cognitive–behavioural therapy can improve pain as well as improving quality of life.

    ‘it’s all about the bowel movements. It’s all about how often you go to the loo. … I don’t think they focus on the pain so much.’ 1

    Introduction

    The majority of individuals with inflammatory bowel disease (IBD) experience pain regularly2 3 and this has a negative impact on daily activities4 while being associated with a poorer quality of life.3 5 Pain management approaches frequently focus on reducing inflammation yet, one-third of individuals continue to experience pain despite mucosal healing6 7 and pain often persists despite ‘clinical remission’.8 Furthermore, many pain medications such as opioids are ineffective for pain arising from the gut and for chronic pain lasting more than 3 months. Qualitative studies indicate that individuals with IBD pain can feel discredited, misunderstood and/or frustrated that lack of knowledge among clinicians leads to pain being insufficiently managed1 9 while long-term, trusting patient–clinician relationships with regular review of pain were valued by patients.10 In this practical guide, we describe the pathophysiology of chronic abdominal pain in IBD, outline pharmacological, psychological, dietary and lifestyle approaches to management.

    Pathophysiology of chronic pain in IBD

    A recent international consensus defines pain as ‘an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage’.11 Acute pain may prevent harm by initiating withdrawal from danger; however, this definition acknowledges that pain often exists in the absence of tissue damage and in the presence of normal investigations. Chronic pain is a subjective experience unique to each individual and influenced by peripheral, central, environmental and psychosocial factors, all of which must be considered to understand and improve the individual’s experience (figure 1).

    Figure 1
    Figure 1

    Pathophysiology of pain in inflammatory bowel disease. *N-methyl-D-aspartate.

    Pathophysiology: viscera

    Noxious stimuli in the intestine activate pain receptors; chemoreceptors are triggered by inflammatory mediators while mechanoreceptors are triggered by bowel distention. Bowel distention may occur because of strictures, adhesions or luminal gas. Chronic inflammation results in visceral hypersensitivity by increasing mucosal signalling molecules, changing ion channel expression and lowering the threshold for nerve activation.12 13

    Pathophysiology: dorsal horn

    Impulses are transmitted via nerves to the spinal cord where they synapse on second order nerves in the dorsal horn ganglia. Visceral inflammation has been shown to increase nerve excitability at this level via changes to the N-methyl-D-aspartate receptor and this is associated with hypersensitivity.13 14

    Pathophysiology: hypothalamus–pituitary–axis

    Pain can result in activation of the hypothalamus–pituitary–axis stress pathway, leading to glucocorticoid and catecholamine hormone production. These hormones act centrally to determine the emotional response to pain by integrating past experiences. Previous or current stress results in a heightened perception of pain, as shown on functional brain imaging.15 Stress also activates the autonomic nervous system which increases blood pressure and diverts blood away from the gastrointestinal (GI) tract towards the brain and muscles. This can result in delayed gut transit and abdominal discomfort.16 Finally, stress hormones modify immune function through cytokine production, which can lead to painful disease flares.13

    Pathophysiology: central processing

    Pain signals travel via nerves in the spinal cord to the thalamus and reticular formation before being processed in the cerebral cortex. This processing may be affected by IBD, even in remission, Crohn’s disease (CD) patients had decreased grey matter volumes in areas of the brain involved with processing pain sensation when compared with controls, a finding also noted in other chronic pain syndromes.17

    Pathophysiology: psychological factors

    Emotional and cognitive processes can reduce pain inhibition signals travelling from the brain to the gut, resulting in gut hypersensitivity and persistent abdominal pain.12 18 Additionally, psychological stress has been associated with altered gut microbiota19 which leads to pain via altered intestinal cytokines and bowel distention. Inflammation and physical processes often initiate pain, but chronic pain may be maintained by psychological factors such as mood disorders, ‘perceived stress’ and ‘pain-catastrophising’, all of which were associated with increased IBD pain in a systematic review.20

    Coexistent irritable bowel syndrome

    A common source of pain in IBD is coexistent irritable bowel syndrome (IBS), a disorder of gut–brain interaction, which affects around one-third of individuals with IBD21 and is 2–3 times more common in patients with IBD in remission than in the general population.22 Chronic IBD pain and IBS share common pathophysiological features, and it is likely that there is an overlap between the two processes including low-grade mucosal inflammation, neuroimmune interactions22 23 and alterations in the gut microbiota.13 23 Additionally, there is a high prevalence of anxiety and depression in individuals with IBD24 and those with anxiety and depression are more likely to experience IBS symptoms.22

    Thus IBS-IBD overlap may explain why many past, current and proposed treatments for chronic IBD pain are those that may also improve IBS symptoms. It should, however, be noted that a qualitative study reported that many patients with IBD find the label of IBS unhelpful.25

    Managing chronic abdominal pain in IBD

    Cochrane reviews of randomised pain intervention studies for ulcerative colitis (UC) and CD had very low certainty of evidence due to small numbers as well as heterogeneity among studies and risk of bias26 27 and further high-quality research is needed to improve both pharmacological and non-pharmacological approaches.28 Here, we present a summary of the data available for managing chronic IBD-related abdominal pain interventions, as well as a checklist for assessing chronic pain in IBD (online supplemental information 1). In this review, we discuss CD and UC together under the umbrella of ‘IBD’, first because IBD chronic pain literature does not differentiate between the diseases (or has similar outcomes for both CD and UC) and second, because a similar prevalence of pain is reported in 4176 CD and 4255 UC individuals in the IBD BOOST study (17% UC vs 25% CD) and in quiescent CD and UC (60.2% vs 62.5%, respectively).29 30 Holistic management of chronic pain is paramount, addressing pharmacological, psychological and lifestyle approaches (figure 2).

    Supplemental material

    Figure 2
    Figure 2

    Approaches to pain management with most patients requiring an integrated, holistic and multimodal approach. FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols; NSAIDs, non-steroidal anti-inflammatory drugs.

    Managing chronic abdominal pain in IBD: modifiable causes for abdominal pain

    To manage pain, modifiable causes should be identified and treated (see figure 3). If an individual reports feeling pain despite having no evidence of a disease flare, it is important to rule out the causes below.31

    Figure 3
    Figure 3

    Modifiable causes for abdominal pain. †see Miller et al.29 SIBO, small intestinal bacterial overgrowth.

    Managing chronic abdominal pain in IBD: pharmacological approaches

    Non-steroidal anti-inflammatory drugs

    Non-visceral inflammatory pain typically responds well to non-steroidal anti-inflammatory drugs (NSAIDs) and NSAID use can alleviate pain associated with axial and peripheral arthropathies that occur in IBD. However, many clinicians are wary of NSAIDs due to perceived risk of IBD flares,32 although a recent systematic review including two randomised controlled trials (RCTs) demonstrated no statistically significant increase in the risk of disease flares33 and, where increased risk has been demonstrated, it appears to be highest in ileal CD,33 with frequent use (more than five times per month)34 and with COX-1 inhibitors.33

    NSAIDs have a role in pain control in select patients with IBD, particularly in the context of extraintestinal musculoskeletal symptoms, however, caution should be exercised regarding the risk of disease flares; selective COX-2 inhibitors may be preferable to minimise this risk.

    Antispasmodics

    There are no studies directly reviewing the use of antispasmodics in IBD and most data relate to their use in IBS. As outlined above, IBS commonly coexists alongside IBD and the American Gastroenterological Association advise antispasmodics for patients with IBD with IBS/functional symptoms.35 Systematic reviews, including a network meta-analysis of IBS RCTs, have demonstrated that antispasmodic drugs and peppermint oil are significantly more efficacious than placebo at 4–12 weeks.36 Caution must be exercised in patients with risk of obstruction as anticholinergic effects may mask or exacerbate symptoms.

    Antispasmodics provide symptom control for IBS, however, consider the risk of side effects, including constipation, prior to use in IBD.

    Opioids

    Opioids are very effective in treating acute pain or pain caused by cancer. However, for chronic pain there is limited evidence of any benefit and for patients with IBD, opioids do not improve pain or quality-of-life scores and reduced hospital opioid prescribing does not worsen pain scores.37–39

    Instead, long-term opioid use may be associated with increased pain and side effects including constipation, nausea, vomiting, immunosuppression, sexual dysfunction, addiction, sedation and respiratory depression.40–44 Regular use of strong opioids in IBD has been associated with a twofold increase in premature mortality45 and is a predictor for serious infection.46

    Opioids are frequently prescribed to manage coexisting musculoskeletal and rheumatological complaints,47 despite there being no proven benefit of chronic opioid use above simple analgesia in these conditions48 and The National Institute for Health and Care Excellence (NICE) guidelines do not recommend the use of opioids in musculoskeletal symptom control.49–51 Likewise, the British Society of Gastroenterology guidelines discourage opioid use in IBD52 and the Faculty of Pain Medicine advises against the use of opioids for chronic pain beyond 2–4 weeks of modest doses.41

    Atypical opioids

    Partial opioid receptor agonists such as buprenorphine offer analgesic effects with reduced withdrawal effects, less dysphoria and an improved safety profile compared with regular opioids. However, there remain long-term side effect and dependence risks.53 Naltrexone antagonises opioid receptors, yet at low doses it has paradoxical analgesic effects. Small studies have shown benefit in pain control in IBD with a favourable side effect profile compared with regular opioids, but this requires further evaluation.54 Loperamide and diphenoxylate, which do not readily cross the blood–brain barrier, exploit the antidiarrhoeal and antisecretory effects of opioids and animal models have indicated that loperamide may also reduce pain via blockade of sodium channels.55 Significant improvement in IBD abdominal pain was seen in individuals treated with loperamide for 1 week compared with placebo.56

    Avoid opioid prescribing for chronic pain in IBD. Where opioid prescribing is unavoidable this should be a joint decision with the patient to trial a modest dose over 2–4 weeks with counselling that those who do not achieve useful pain relief within this period are unlikely to gain benefit in the long term.26 See Opioid Aware https://www.fpm.ac.uk/opioids-awareforfurtherguidance.

    Antidepressant medications

    Antidepressant medications (ADMs), such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), regulate the neurotransmitters serotonin, norepinephrine and corticotropin-releasing factor to alter gut motility and modulate signals between the gut and the brain resulting in an overall reduction in pain.57 These medications may also improve pain by treating coexistent IBS and it has been suggested that ADMs could modify IBD activity, but a systematic review found the evidence inconclusive in this regard.58

    Tricyclic antidepressants

    Certain TCAs, including amitriptyline and nortriptyline, are licensed in the UK to treat neuropathic pain and are used off-licence for abdominal pain not responding to first-line treatment.59 TCAs are also used to treat depression but the dosage for pain is much lower. In a retrospective cohort study of TCA use in patients with mild or inactive IBD, 85.2% of whom had abdominal pain, there was a moderate improvement in global well-being scores. The improvement was similar to that seen in IBS treated with TCAs and pain scores were not recorded.60 A systematic review of IBS treatment showed that low dose TCA treatment had a lower relative risk of abdominal pain compared with placebo.61 Side effects of TCAs include sedation, overdose toxicity, cardiotoxic effects and anticholinergic effects. Constipation may be beneficial in individuals for whom diarrhoea is an issue, while taking doses at night can use TCA’s sedative effect.

    SSRIs and SNRIs

    Few studies have examined the effect of SSRIs/SNRIs on pain in IBD and those that have generally show little benefit.62–64

    Two systematic reviews of ADMs in IBS showed no significant effect of SSRIs on abdominal pain.36 61 The side effects of SSRIs and SNRIs include agitation, insomnia, sexual dysfunction, nausea and diarrhoea and these must be taken into account when considering their use, particularly in individuals troubled by increased stool frequency.57

    Low-dose TCAs may help manage pain in IBD and coexistent IBS. There is little evidence for the benefit of SSRIs or SNRIs.

    Gabapentinoids

    The gabapentinoids gabapentin and pregabalin are analogues of gamma-aminobutyric acid (GABA) with anticonvulsant, central and possibly peripheral, analgesic actions. Anti-inflammatory properties of gabapentinoids have been demonstrated in animal models and may represent another mode of action by which pain in IBD can be altered.65

    The impact of gabapentinoids on IBD pain has not been directly studied, instead benefit has been extrapolated from trials in chronic pancreatitis, oesophageal hyperalgesia and rectal sensitivity.

    For patients with IBS with rectal hypersensitivity, pregabalin increased distension sensory thresholds to normal levels66 and gabapentin significantly increased threshold pressures for bloating, discomfort and pain in IBS with diarrhoea.66 67 For chronic pancreatitis, pregabalin treatment significantly improved pain relief when compared with placebo68 and pregabalin prevented proximal oesophageal hyperalgesia following oesophageal acidification.69

    The substantial side effect profile includes somnolence, GI upset and risk of dependency. Somewhat controversially, NICE does not recommend their use for the treatment of chronic pain.70

    Gabapentinoids may improve chronic visceral pain; however, more evidence is required in IBD. Their side effects and the risk of dependency need to be considered carefully.

    Cannabinoids

    The human endocannabinoid system (ECS) is a neuromodulatory system which responds to both endogenous and exogenous cannabinoids, such as Δ9-tetrahydrocannbinol (THC) and cannabidiol (CBD). Cannabinoid receptors are found in the GI tract as well as the central nervous system and the ECS has a role in modulating pain sensation. Observational cohort data indicate that 17.6% of patients with IBD regularly use cannabis and 83.9% of users felt cannabis improved their abdominal pain.71 Two small studies have shown improved IBD clinical scores in individuals smoking or inhaling cannabis72 73; however, follow-up was short and abdominal pain was not specifically evaluated.

    Regression analysis linked prolonged cannabis use with an increased risk of surgery after adjusting for tobacco smoking and demographic status.71

    Medical cannabis is not approved for use in IBD and there is currently no evidence of its benefit in treating IBD-related abdominal pain.

    Managing chronic abdominal pain in IBD: psychological approaches

    A recent systematic review reported six studies using behavioural therapies to manage IBD-related pain and included individuals who were predominantly in remission.74 The review concluded that relaxation techniques and changing cognitions show promise but in view of the scarcity of evidence, further research is warranted. The IBD-BOOST study explores a tailored, online, facilitated cognitive behavioural intervention for symptom control.29 Of all 8486 patients included in the initial survey, 42% report wanting support for pain management and the results of the RCT of a facilitated online behavioural therapy intervention are keenly awaited; potentially offering a pragmatic approach to chronic pain management in IBD. A small cohort study demonstrated a significant reduction in abdominal pain in stress management groups compared with those without stress management although there was no adjustment for IBD activity.75 A study of 20 patients allocated to relaxation training had significantly lower pain scores than a group of 20 allocated to attention control76 and relaxation techniques improved pain in patients with IBD randomised to intervention compared with waiting list controls.77 Studies of adolescent and paediatric participants have shown improved pain scores through cognitive behavioural therapy (CBT) and coping skills; however, the results are not widely representative with two studies including only adolescent females, another only those with anxiety disorder, and the effect of high attrition rates were noted.78–81 IBD-specific CBT improved quality of life and decreased anxiety and depression in patients with IBD with poor quality of life.82 Acceptance and commitment therapy (ACT) and multiconvergent therapy improve several outcomes in IBD including quality of life but the impact on pain has not been specifically assessed.83 84

    With regard to the impact of behavioural therapies on IBS, a recent systematic review demonstrated that CBT and gut-directed hypnotherapy had the most evidence for efficacy however, there was a high risk of bias.85 An RCT of 431 adults with functional bowel disorders showed that CBT was significantly more effective than education in improving quality of life despite having little effect on pain, and may enable an improved ability to live with pain.86

    A systematic review of the use of mindfulness for pain control concluded that existing evidence was limited and inconclusive.87 An IBD-specific review showed no effect on symptoms, although mindfulness did improve quality of life.88 While overall IBS symptoms can be significantly improved long term with hypnotherapy, no studies in IBD-related pain have been conducted.89 One study has shown that individuals with UC in remission randomised to gut directed hypnotherapy had clinical relapse 78 days later than those randomised to attention control alone, however, pain was not directly assessed and there was no difference in quality of life.90

    There is some limited evidence regarding psychological approaches in IBD-related pain with CBT improving overall quality of life, coping mechanisms and pain.

    Diet and lifestyle approaches

    The low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet contains low levels of FODMAP. These carbohydrates are poorly absorbed in the small intestine, are highly osmotic and are rapidly fermented by bacteria in the gut. This leads to fluid and gas distention of the bowel which may result in symptoms such as bloating, flatulence, cramping and diarrhoea. A diet reduced in FODMAPs, followed by FODMAP reintroduction, is well recognised as an effective approach to managing abdominal pain in IBS91 and its role in reducing abdominal pain in IBD was supported in a recent systematic review.92 93 An additional two studies indicate significantly more patients with IBS symptoms and quiescent IBD had resolved or improved abdominal pain, after 6–8 weeks of low-FODMAP diet.94 95 Low-FODMAP diets are low in fibre and may lead to constipation; compliance may be challenging due to the diet’s restrictive nature and it has been linked to a reduction in total bacteria and butyrate-producing bacteria, which are important for anti-inflammatory and immune regulatory functions.92 It is, therefore, important that the food reintroduction phase of the diet is followed, under the supervision of a dietician.

    A comparison of the specific carbohydrate diet (SCD) and Mediterranean diet (MD) in IBD found that both improved abdominal pain at week 6 but, while the SCD may lead to deficiencies in key vitamins, an MD is generally easy to follow.96 Many individuals with IBD follow a gluten free diet (GFD) in the absence of coeliac disease. A recent systematic review and meta-analysis of dietary interventions for induction and maintenance of remission in IBD reported mixed findings; one study showed that symptoms, including pain, improved in two-thirds of individuals while a prospective study found no variation in hospitalisations or flares but a poorer quality of life in those with GFD.97 Further research is needed in this area.98

    Moderate exercise can improve quality of life in IBD and improve GI symptoms in IBS, however, the effect on pain in IBD has not been studied.35

    The FODMAP diet offers short-term benefit to those with coexistent IBS and is best carried out for a time limited period, under the supervision of a dietician.

    Conclusion

    Managing chronic pain in IBD continues to be a challenge for clinicians and patients alike. By listening to patients, acknowledging their symptoms and assessing pain with pain severity scales we can begin to manage chronic pain effectively. Few research studies focus specifically on pain in IBD and assessment of specific interventions to improve pain outcomes are badly needed. A collaborative approach between clinician and patient, reviewing disease activity, psychosocial factors, current medications and comorbidities must be undertaken to achieve optimal symptom control.

    Early diagnosis and suppression of inflammation may prevent irreversible central and peripheral changes that contribute to chronic pain. Considering the poor efficacy and side effect profile of many pharmacological agents, notably opioids, the management of chronic pain in IBD should largely comprise non-pharmacological approaches. Psychological approaches have shown promise and further research is needed. In the future, integrated psychological and pain services need to be part of a holistic approach to caring for individuals with IBD (figure 2).

    Ethics statements

    Patient consent for publication

    References

    1. ↵
      2. Sweeney L ,
      3. Moss-Morris R ,
      4. Czuber-Dochan W , et al
      . It’s about willpower in the end. You’ve got to keep going’: a qualitative study exploring the experience of pain in inflammatory bowel disease. Br J Pain 2019;13:201–13. doi:10.1177/2049463719844539
      OpenUrl
    2. ↵
      2. Schirbel A ,
      3. Reichert A ,
      4. Roll S , et al
      . Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010;16:3168–77. doi:10.3748/wjg.v16.i25.3168
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      2. Zeitz J ,
      3. Ak M ,
      4. Müller-Mottet S , et al
      . Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLOS ONE 2016;11:e0156666. doi:10.1371/journal.pone.0156666
    4. ↵
      2. Devlen J ,
      3. Beusterien K ,
      4. Yen L , et al
      . The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis 2014;20:545–52. doi:10.1097/01.MIB.0000440983.86659.81
      OpenUrlCrossRefPubMed
    5. ↵
      2. Lönnfors S ,
      3. Vermeire S ,
      4. Greco M , et al
      . IBD and health-related quality of life -- discovering the true impact. J Crohns Colitis 2014;8:1281–6. doi:10.1016/j.crohns.2014.03.005
      OpenUrlCrossRefPubMed
    6. ↵
      2. Shah SC ,
      3. Colombel JF ,
      4. Sands BE , et al
      . Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 2016;43:317–33. doi:10.1111/apt.13475
      OpenUrlCrossRefPubMed
    7. ↵
      2. Shah SC ,
      3. Colombel J-F ,
      4. Sands BE , et al
      . Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245–55. doi:10.1016/j.cgh.2016.01.015
      OpenUrlPubMed
    8. ↵
      2. Colombel JF ,
      3. Sandborn WJ ,
      4. Reinisch W , et al
      . Infliximab, azathioprine, or combination therapy for crohn’s disease. N Engl J Med 2010;362:1383–95. doi:10.1056/NEJMoa0904492
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      2. Bernhofer EI ,
      3. Masina VM ,
      4. Sorrell J , et al
      . The pain experience of patients hospitalized with inflammatory bowel disease. Gastroenterol Nurs 2017;40:200–7. doi:10.1097/SGA.0000000000000137
      OpenUrl
    10. ↵
      2. Balbale SN ,
      3. Iroz CB ,
      4. Schäfer WLA , et al
      . A missing piece of the puzzle: patient and provider perspectives on pain management needs and opioid prescribing in inflammatory bowel disease care. Crohns Colitis 360 2022;4:otac033. doi:10.1093/crocol/otac033
    11. ↵
      2. Raja SN ,
      3. Carr DB ,
      4. Cohen M , et al
      . The revised International association for the study of pain definition of pain: concepts, challenges, and compromises. Pain 2020;161:1976–82. doi:10.1097/j.pain.0000000000001939
      OpenUrlCrossRefPubMed
    12. ↵
      2. Zielińska A ,
      3. Sałaga M ,
      4. Włodarczyk M , et al
      . Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. Int J Colorectal Dis 2019;34:217–27. doi:10.1007/s00384-018-3218-0
      OpenUrlPubMed
    13. ↵
      2. Srinath A ,
      3. Young E ,
      4. Szigethy E
      . Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014;20:2433–49. doi:10.1097/MIB.0000000000000170
      OpenUrlCrossRefPubMed
    14. ↵
      2. Willert RP ,
      3. Woolf CJ ,
      4. Hobson AR , et al
      . The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-d-aspartate receptor. Gastroenterology 2004;126:683–92. doi:10.1053/j.gastro.2003.11.047
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      2. Wong RK ,
      3. Van Oudenhove L ,
      4. Li X , et al
      . Visceral pain perception in patients with irritable bowel syndrome and healthy volunteers is affected by the MRI scanner environment. UEG Journal 2016;4:132–41. doi:10.1177/2050640615580888
      OpenUrl
    16. ↵
      2. Abdallah CG ,
      3. Geha P
      . Chronic pain and chronic stress: two sides of the same coin? Chronic stress thousand oaks Calif. Chronic Stress (Thousand Oaks) 2017:2470547017704763. doi:10.1177/2470547017704763
    17. ↵
      2. Agostini A ,
      3. Benuzzi F ,
      4. Filippini N , et al
      . New insights into the brain involvement in patients with crohn’s disease: a Voxel-based morphometry study. Neurogastroenterol Motil 2013;25:147–e82. doi:10.1111/nmo.12017
      OpenUrlCrossRefPubMed
    18. ↵
      2. Hurtado-Lorenzo A ,
      3. Honig G ,
      4. Weaver SA , et al
      . Chronic abdominal pain in IBD research initiative: unraveling biological mechanisms and patient heterogeneity to personalize treatment and improve clinical outcomes. Crohns Colitis 360 2021;3:otab034. doi:10.1093/crocol/otab034
    19. ↵
      2. Simpson CA ,
      3. Diaz-Arteche C ,
      4. Eliby D , et al
      . The gut microbiota in anxiety and depression - a systematic review. Clin Psychol Rev 2021;83:101943. doi:10.1016/j.cpr.2020.101943
      OpenUrlCrossRefPubMed
    20. ↵
      2. Sweeney L ,
      3. Moss-Morris R ,
      4. Czuber-Dochan W , et al
      . Systematic review: psychosocial factors associated with pain in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:715–29. doi:10.1111/apt.14493
      OpenUrlCrossRef
    21. ↵
      2. Fairbrass KM ,
      3. Costantino SJ ,
      4. Gracie DJ , et al
      . Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:1053–62. doi:10.1016/S2468-1253(20)30300-9
      OpenUrl
    22. ↵
      2. Simrén M ,
      3. Axelsson J ,
      4. Gillberg R , et al
      . Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389–96. doi:10.1111/j.1572-0241.2002.05475.x
      OpenUrlCrossRefPubMed
    23. ↵
      2. Ohman L ,
      3. Simrén M
      . Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163–73. doi:10.1038/nrgastro.2010.4
      OpenUrlCrossRefPubMed
    24. ↵
      2. Jayasooriya N ,
      3. Blackwell J ,
      4. Saxena S , et al
      . Antidepressant medication use in inflammatory bowel disease: a nationally representative population‐based study. Aliment Pharmacol Ther 2022;55:1330–41. doi:10.1111/apt.16820
      OpenUrl
    25. ↵
      2. Huisman D ,
      3. Sweeney L ,
      4. Bannister K , et al
      . Irritable bowel syndrome in inflammatory bowel disease: distinct, intertwined, or unhelpful? Views and experiences of patients. Cogent Psychology 2022;9:2050063. doi:10.1080/23311908.2022.2050063
    26. ↵
      2. Sinopoulou V ,
      3. Gordon M ,
      4. Akobeng AK , et al
      . Interventions for the management of abdominal pain in crohn’s disease and inflammatory bowel disease. Cochrane Database Syst Rev 2021;11:CD013531. doi:10.1002/14651858.CD013531.pub2
    27. ↵
      1. Cochrane Gut Group,
      2. Sinopoulou V ,
      3. Gordon M , et al
      . Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst Rev 2021;2021. doi:10.1002/14651858.CD013589.pub2
    28. ↵
      1. Inflammatory Bowel Disease Priority Setting Partnership
      . Inflammatory bowel disease top ten. (James LIND alliance priority setting partnerships). James Lind Alliance; 2015. Available: https://www.jla.nihr.ac.uk/priority-setting-partnerships/inflammatory-bowel-disease/top-10-priorities/ [Accessed 24 Oct 2022].
    29. ↵
      2. Hart A ,
      3. Miller L ,
      4. Hamborg T , et al
      . DOP59 what is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants. J Crohns Colitis 2023;17:i130–2. doi:10.1093/ecco-jcc/jjac190.0099
      OpenUrl
    30. ↵
      2. Coates MD ,
      3. Johri A ,
      4. Gorrepati VS , et al
      . Abdominal pain in quiescent inflammatory bowel disease. Int J Colorectal Dis 2021;36:93–102. doi:10.1007/s00384-020-03727-3
      OpenUrl
    31. ↵
      2. Miller C ,
      3. Emmanuel A ,
      4. Zarate-Lopez N , et al
      . Constipation in ulcerative colitis: pathophysiology and practical management. Frontline Gastroenterol 2021;12:493–9. doi:10.1136/flgastro-2020-101566
      OpenUrlAbstract/FREE Full Text
    32. ↵
      2. Takeuchi K ,
      3. Smale S ,
      4. Premchand P , et al
      . Prevalence and mechanism of nonsteroidal anti-inflammatory drug–induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196–202. doi:10.1016/s1542-3565(05)00980-8
      OpenUrlCrossRefPubMedWeb of Science
    33. ↵
      2. Moninuola OO ,
      3. Milligan W ,
      4. Lochhead P , et al
      . Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther 2018;47:1428–39. doi:10.1111/apt.14606
      OpenUrl
    34. ↵
      2. Long MD ,
      3. Kappelman MD ,
      4. Martin CF , et al
      . Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. J Clin Gastroenterol 2016;50:152–6. doi:10.1097/MCG.0000000000000421
      OpenUrlCrossRefPubMed
    35. ↵
      2. Colombel JF ,
      3. Shin A ,
      4. Gibson PR
      . AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2019;17:380–90. doi:10.1016/j.cgh.2018.08.001
      OpenUrl
    36. ↵
      2. Black CJ ,
      3. Yuan Y ,
      4. Selinger CP , et al
      . Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2020;5:117–31. doi:10.1016/S2468-1253(19)30324-3
      OpenUrl
    37. ↵
      2. Coates MD ,
      3. Seth N ,
      4. Clarke K , et al
      . Opioid analgesics do not improve abdominal pain or quality of life in crohn’s disease. Dig Dis Sci 2020;65:2379–87. doi:10.1007/s10620-019-05968-x
      OpenUrl
    38. ↵
      2. Berry SK ,
      3. Takakura W ,
      4. Bresee C , et al
      . Pain in inflammatory bowel disease is not improved during hospitalization: the impact of opioids on pain and healthcare utilization. Dig Dis Sci 2020;65:1777–83. doi:10.1007/s10620-019-05906-x
      OpenUrl
    39. ↵
      2. Kaimakliotis P ,
      3. Ramadugu A ,
      4. Kang J , et al
      . Targeted housestaff intervention reduces opioid use without worsening patient-reported pain scores and improves outcomes among patients with IBD: the “IBD pain ladder Int J Colorectal Dis 2021;36:1193–200. doi:10.1007/s00384-021-03852-7
      OpenUrl
    40. ↵
      2. Chou R ,
      3. Gordon DB ,
      4. de Leon-Casasola OA , et al
      . Management of postoperative pain: a clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. J Pain 2016;17:131–57. doi:10.1016/j.jpain.2015.12.008
      OpenUrlCrossRefPubMed
    41. ↵
      1. Faculty of Pain Medicine
      . The effectiveness of opioids for long term pain. Opioids Aware, Available: https://www.fpm.ac.uk/opioids-aware-clinical-use-opioids/opioids-long-term-pain [Accessed 05 Aug 2022].
    42. ↵
      2. Poole DP ,
      3. Pelayo J ,
      4. Scherrer G , et al
      . Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. Gastroenterology 2011;141:982–991. doi:10.1053/j.gastro.2011.05.042
      OpenUrlCrossRefPubMed
    43. ↵
      2. Sobczak M ,
      3. Sałaga M ,
      4. Storr MA , et al
      . Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 2014;49:24–45. doi:10.1007/s00535-013-0753-x
      OpenUrlCrossRefPubMed
    44. ↵
      2. Reja M ,
      3. Hajela N ,
      4. Makar M , et al
      . One-year risk of opioid use disorder after index hospitalization for inflammatory bowel disease. Int J Colorectal Dis 2020;35:2081–7. doi:10.1007/s00384-020-03691-y
      OpenUrl
    45. ↵
      2. Burr NE ,
      3. Smith C ,
      4. West R , et al
      . Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol 2018;16:534–41. doi:10.1016/j.cgh.2017.10.022
      OpenUrl
    46. ↵
      2. Lichtenstein GR ,
      3. Feagan BG ,
      4. Cohen RD , et al
      . Serious infections and mortality in association with therapies for crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol 2006;4:621–30. doi:10.1016/j.cgh.2006.03.002
      OpenUrlCrossRefPubMedWeb of Science
    47. ↵
      2. Baillie S ,
      3. Limdi JK ,
      4. Bassi A , et al
      . Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project. Frontline Gastroenterol 2023:flgastro–2023. doi:10.1136/flgastro-2023-102423
    48. ↵
      2. Lin I ,
      3. Wiles L ,
      4. Waller R , et al
      . What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: systematic review. Br J Sports Med 2020;54:79–86. doi:10.1136/bjsports-2018-099878
      OpenUrlAbstract/FREE Full Text
    49. ↵
      1. National Institute for Health and Care Excellence
      . Rheumatoid arthritis in adults: management. report no.: NG100. 2018. Available: www.nice.org.uk/guidance/ng100 [Accessed 09 Aug 2022].
    50. ↵
      1. National Institute for Health and Care Excellence
      . Osteoarthritis in over 16S: diagnosis and management. report no.: NICE guideline [NG226]. 2022. Available: https://www.nice.org.uk/guidance/ng226 [Accessed 04 Feb 2023].
    51. ↵
      1. National Institute for Health and Care Excellence
      . Low back pain and sciatica in over 16S: assessment and management. report no.: NICE guideline [NG59]. 2020. Available: https://www.nice.org.uk/guidance/NG59 [Accessed 04 Feb 2023].
    52. ↵
      2. Lamb CA ,
      3. Kennedy NA ,
      4. Raine T , et al
      . British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1–106. doi:10.1136/gutjnl-2019-318484
      OpenUrlAbstract/FREE Full Text
    53. ↵
      2. Johnson RE ,
      3. Fudala PJ ,
      4. Payne R
      . Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297–326. doi:10.1016/j.jpainsymman.2004.07.005
      OpenUrlCrossRefPubMedWeb of Science
    54. ↵
      2. Kim PS ,
      3. Fishman MA
      . Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep 2020;24:64. doi:10.1007/s11916-020-00898-0
    55. ↵
      2. Wu Y ,
      3. Zou B ,
      4. Liang L , et al
      . Loperamide inhibits sodium channels to alleviate inflammatory hyperalgesia. Neuropharmacology 2017;117:282–91. doi:10.1016/j.neuropharm.2017.02.010
      OpenUrl
    56. ↵
      2. van Outryve M ,
      3. Toussaint J
      . Loperamide oxide for the treatment of chronic diarrhoea in crohn’s disease. J Int Med Res 1995;23:335–41. doi:10.1177/030006059502300503
      OpenUrlCrossRefPubMed
    57. ↵
      2. Mikocka-Walus A ,
      3. Ford AC ,
      4. Drossman DA
      . Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:184–92. doi:10.1038/s41575-019-0259-y
      OpenUrl
    58. ↵
      2. Mikocka-Walus AA ,
      3. Turnbull DA ,
      4. Moulding NT , et al
      . Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006;2:24. doi:10.1186/1745-0179-2-24
      OpenUrlCrossRefPubMed
    59. ↵
      1. Joint Formulary Comittee
      . Amitriptyline hydrochloride:indications and dose. 82nd ed. British National Formulary, n.d.
    60. ↵
      2. Iskandar HN ,
      3. Cassell B ,
      4. Kanuri N , et al
      . Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423–9. doi:10.1097/MCG.0000000000000049
      OpenUrlCrossRefPubMed
    61. ↵
      2. Ford AC ,
      3. Lacy BE ,
      4. Harris LA , et al
      . Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019;114:21–39. doi:10.1038/s41395-018-0222-5
      OpenUrlCrossRefPubMed
    62. ↵
      2. Mikocka-Walus A ,
      3. Hughes PA ,
      4. Bampton P , et al
      . Fluoxetine for maintenance of remission and to improve quality of life in patients with crohn’s disease: a pilot randomized placebo-controlled trial. J Crohns Colitis 2017;11:509–14. doi:10.1093/ecco-jcc/jjw165
      OpenUrlPubMed
    63. ↵
      2. Walker EA ,
      3. Gelfand MD ,
      4. Gelfand AN , et al
      . The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry 1996;18:220–9. doi:10.1016/0163-8343(96)00036-9
      OpenUrlCrossRefPubMedWeb of Science
    64. ↵
      2. Daghaghzadeh H ,
      3. Naji F ,
      4. Afshar H , et al
      . Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. J Res Med Sci 2015;20:595. doi:10.4103/1735-1995.165969
      OpenUrlCrossRefPubMed
    65. ↵
      2. de Brito TV ,
      3. Júnior GJD ,
      4. da Cruz Júnior JS , et al
      . Gabapentin attenuates intestinal inflammation: role of PPAR-gamma receptor. Eur J Pharmacol 2020;873:172974. doi:10.1016/j.ejphar.2020.172974
      OpenUrl
    66. ↵
      2. Docherty MJ ,
      3. Jones RCW ,
      4. Wallace MS
      . Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011;7:592–601.
      OpenUrlPubMed
    67. ↵
      2. Lee KJ ,
      3. Kim JH ,
      4. Cho SW
      . Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:981–8. doi:10.1111/j.1365-2036.2005.02685.x
      OpenUrlCrossRefPubMedWeb of Science
    68. ↵
      2. Farrokhyar F ,
      3. Marshall JK ,
      4. Easterbrook B , et al
      . Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38–46. doi:10.1097/01.mib.0000195391.49762.89
      OpenUrlCrossRefPubMedWeb of Science
    69. ↵
      2. Srinath AI ,
      3. Walter C ,
      4. Newara MC , et al
      . Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol 2012;5:339–57. doi:10.1177/1756283X12446158
      OpenUrlCrossRefPubMed
    70. ↵
      1. National Institute for Health and Care Excellence
      . Chronic pain (primary and secondary) in over sixteens: assessment of all chronic pain and management of chronic primary pain. 2021. Available: https://www.nice.org.uk/guidance/ng193
    71. ↵
      2. Storr M ,
      3. Devlin S ,
      4. Kaplan GG , et al
      . Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with crohn’s disease. Inflamm Bowel Dis 2014;20:472–80. doi:10.1097/01.MIB.0000440982.79036.d6
      OpenUrlCrossRefPubMed
    72. ↵
      2. Lahat A ,
      3. Lang A ,
      4. Ben-Horin S
      . Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 2012;85:1–8. doi:10.1159/000332079
      OpenUrlPubMed
    73. ↵
      2. Naftali T ,
      3. Bar-Lev Schleider L ,
      4. Dotan I , et al
      . Cannabis induces a clinical response in patients with crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11:1276–80. doi:10.1016/j.cgh.2013.04.034
      OpenUrlCrossRefPubMed
    74. ↵
      2. Norton C ,
      3. Czuber-Dochan W ,
      4. Artom M , et al
      . Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:115–25. doi:10.1111/apt.14108
      OpenUrlPubMed
    75. ↵
      2. García-Vega E ,
      3. Fernandez-Rodriguez C
      . A stress management programme for crohn’s disease. Behav Res Ther 2004;42:367–83. doi:10.1016/S0005-7967(03)00146-3
      OpenUrlCrossRefPubMed
    76. ↵
      2. Shaw L ,
      3. Ehrlich A
      . Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain 1987;29:287–93. doi:10.1016/0304-3959(87)90043-1
      OpenUrlCrossRefPubMedWeb of Science
    77. ↵
      2. Mizrahi MC ,
      3. Reicher-Atir R ,
      4. Levy S , et al
      . Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol Health 2012;27:1463–79. doi:10.1080/08870446.2012.691169
      OpenUrlCrossRefPubMedWeb of Science
    78. ↵
      2. Reed-Knight B ,
      3. McCormick M ,
      4. Lewis JD , et al
      . Participation and attrition in a coping skills intervention for adolescent girls with inflammatory bowel disease. J Clin Psychol Med Settings 2012;19:188–96. doi:10.1007/s10880-011-9269-9
      OpenUrlPubMed
    79. ↵
      2. McCormick M ,
      3. Reed-Knight B ,
      4. Lewis JD , et al
      . Coping skills for reducing pain and somatic symptoms in adolescents with IBD. Inflamm Bowel Dis 2010;16:2148–57. doi:10.1002/ibd.21302
      OpenUrlCrossRefPubMedWeb of Science
    80. ↵
      2. Reigada LC ,
      3. Benkov KJ ,
      4. Bruzzese J-M , et al
      . Integrating illness concerns into cognitive behavioral therapy for children and adolescents with inflammatory bowel disease and co-occurring anxiety. J Spec Pediatr Nurs 2013;18:133–43. doi:10.1111/jspn.12019
      OpenUrlCrossRefPubMed
    81. ↵
      2. Hayutin LG ,
      3. Blount RL ,
      4. Lewis JD , et al
      . Skills-based group intervention for adolescent girls with inflammatory bowel disease. Clinical Case Studies 2009;8:355–65. doi:10.1177/1534650109342745
      OpenUrlCrossRef
    82. ↵
      2. Bennebroek Evertsz’ F ,
      3. Sprangers MAG ,
      4. Sitnikova K , et al
      . Effectiveness of cognitive–behavioral therapy on quality of life, anxiety, and depressive symptoms among patients with inflammatory bowel disease: a multicenter randomized controlled trial. J Consult Clin Psychol 2017;85:918–25. doi:10.1037/ccp0000227
      OpenUrlCrossRef
    83. ↵
      2. Bernabeu P ,
      3. van-der Hofstadt C ,
      4. Rodríguez-Marín J , et al
      . Effectiveness of a multicomponent group psychological intervention program in patients with inflammatory bowel disease: a randomized trial. Int J Environ Res Public Health 2021;18:10. doi:10.3390/ijerph18105439
      OpenUrlCrossRef
    84. ↵
      2. Hughes LS ,
      3. Clark J ,
      4. Colclough JA , et al
      . Acceptance and commitment therapy (ACT) for chronic pain: a systematic review and meta-analyses. Clin J Pain 2017;33:552–68. doi:10.1097/AJP.0000000000000425
      OpenUrlCrossRefPubMed
    85. ↵
      2. Black CJ ,
      3. Thakur ER ,
      4. Houghton LA , et al
      . Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 2020;69:1441–51. doi:10.1136/gutjnl-2020-321191
      OpenUrlAbstract/FREE Full Text
    86. ↵
      2. Drossman DA ,
      3. Toner BB ,
      4. Whitehead WE , et al
      . Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1. Gastroenterology 2003;125:19–31. doi:10.1016/s0016-5085(03)00669-3
      OpenUrlCrossRefPubMedWeb of Science
    87. ↵
      2. McClintock AS ,
      3. McCarrick SM ,
      4. Garland EL , et al
      . Brief mindfulness-based interventions for acute and chronic pain: a systematic review. J Altern Complement Med 2019;25:265–78. doi:10.1089/acm.2018.0351
      OpenUrlPubMed
    88. ↵
      2. Ewais T ,
      3. Begun J ,
      4. Kenny M , et al
      . A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. J Psychosom Res 2019;116:44–53. doi:10.1016/j.jpsychores.2018.11.010
      OpenUrlPubMed
    89. ↵
      2. Peters SL ,
      3. Muir JG ,
      4. Gibson PR
      . Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1104–15. doi:10.1111/apt.13202
      OpenUrlPubMed
    90. ↵
      2. Keefer L ,
      3. Taft TH ,
      4. Kiebles JL , et al
      . Gut-directed Hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther 2013;38:761–71. doi:10.1111/apt.12449
      OpenUrlCrossRefPubMed
    91. ↵
      2. Black CJ ,
      3. Staudacher HM ,
      4. Ford AC
      . Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut 2022;71:1117–26. doi:10.1136/gutjnl-2021-325214
      OpenUrlAbstract/FREE Full Text
    92. ↵
      2. Zhan Y ,
      3. Zhan Y ,
      4. Dai S
      . Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clinical Nutrition 2018;37:123–9. doi:10.1016/j.clnu.2017.05.019
      OpenUrlPubMed
    93. ↵
      2. Peng Z ,
      3. Yi J ,
      4. Liu X
      . A low-FODMAP diet provides benefits for functional gastrointestinal symptoms but not for improving stool consistency and Mucosal inflammation in IBD: A systematic review and meta-analysis. Nutrients 2022;14:2072. doi:10.3390/nu14102072
    94. ↵
      2. Tapete G ,
      3. De Bortoli N ,
      4. Ceccarelli L , et al
      . Low-Fodmaps diet improves intestinal symptoms in IBD patients with disease remission: randomized case-control study. Digestive and Liver Disease 2018;50:e195. doi:10.1016/S1590-8658(18)30556-5
    95. ↵
      2. Więcek M ,
      3. Panufnik P ,
      4. Kaniewska M , et al
      . Low-FODMAP diet for the management of irritable bowel syndrome in remission of IBD. Nutrients 2022;14:4562. doi:10.3390/nu14214562
    96. ↵
      2. Lewis JD ,
      3. Sandler RS ,
      4. Brotherton C , et al
      . A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn's disease. Gastroenterology 2021;161:837–52. doi:10.1053/j.gastro.2021.05.047
      OpenUrlPubMed
    97. ↵
      2. Schreiner P ,
      3. Yilmaz B ,
      4. Rossel J-B , et al
      . Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut Microbiota, but no beneficial effects on the course of the disease. UEG Journal 2019;7:767–81. doi:10.1177/2050640619841249
      OpenUrl
    98. ↵
      2. Weaver KN ,
      3. Herfarth H
      . Gluten-free diet in IBD: time for a recommendation? Mol Nutr Food Res 2021;65:e1901274. doi:10.1002/mnfr.201901274

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Twitter @SamanthaIBD

    • Contributors SB researched, drafted and revised the article. RP researched and edited the draft article. SS and CN reviewed and edited the draft article.

    • Funding SS is funded by the National Institute for Health Research (NIHR) School for Public Health Research (SPHR) (PD-SPH-2015), NIHR Northwest London Applied Research. Collaboration (ARC) and Imperial NIHR Biomedical Research Centre. The SPHR is a partnership between the Universities of Sheffield, Bristol, Cambridge, Imperial, University College London and the London School for Hygiene and Tropical Medicine (LSHTM); LiLaC—a collaboration between the Universities of Liverpool and Lancaster; and Fuse—the Centre for Translational Research in Public Health a collaboration between Newcastle, Durham, Northumbria, Sunderland and Teesside Universities. CN received support from a UK National Institute for Health Research programme grant for applied research (grant reference RP-PG-0216-20001).

    • Disclaimer The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or Department of Health and Social Care.

    • Competing interests SB has had speaker arrangements with Takeda and Dr Falk, has received a travel grant from Galapagos and has provided consultancy to Galapagos. RP has provided consultancy to Galapagos. CN has received speaker fees from Ferring, AbbVie, Takeda and Tillotts.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.